
Kliniska studier vid Tema Cancer
–Studier öppna för inklusion inom PO Hematologi–
Här visas de studier som är öppna för patientinklusion inom den medicinska enheten (ME). Studierna är uppdelade på de olika patientflödena. Vidare visas ansvarig prövare, forskningssjuksköterska och planerad och aktuell inklusion inom temat (visas ej utanför Karolinska). Listan uppdateras minst en gång i veckan. -Längst ner finns en förklaring till de olika kolumnerna.
Benmärgssvikt och leukemi
Nr | Namn | Fas |
Startdatum | Ansvarig prövare |
19/051 |
MAATEO. A phase 1 study in MDS, AML and ALL patients to evaluate safety, tolerability and efficacy of Karonudib |
1 |
2019-10-03 |
Stefan Deneberg |
20/016 |
HOVON 150. A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acutemyeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy |
3 |
2021-01-27 |
Martin Jädersten |
20/018 |
EVI-3: Combining Active and Passive DNA Hypomethylation. EVI-3: Combining Active and Passive DNA Hypomethylation A multicenter, randomized, parallel-group, placebo-controlled phase II study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in higher-risk MDS, CMML, and low-blast-count AML |
3 |
2021-04-15 |
Eva Hellström Lindberg |
22/017 |
LD-VenEx. LD-VenEx Clinical Study Protocol: Phase 2 study of azacitidine in combination with low dose intensity venetoclax in patients with acute myeloid leukemia with integration of explorative multi-omics and ex vivo drug screening data |
2 |
2023-05-10 |
Martin Jädersten |
22/064 |
MK3543-006-05 Shorespan-006. A Phase 3 Multi-Center, Randomized, Controlled Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) versus Best Available Therapy (BAT) in Patients with Essential Thrombocythemia who are Resistant to or Intolerant of Hydroxyurea |
3 |
2024-06-01 |
Anna Ravn Landtblom |
23/010 |
MEDAL. Monitoring for Early Detection of relapse in Acute myeloid Leukemia |
Ej tillämpbar |
2023-10-12 |
Martin Jädersten |
24/004 |
MK3543-007 (Shorespan-007). A phase 3, Randomized, Double-blind, Active.Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK3543) versus Hydroxyurea in Cytoreductive Therapy Naive Essential thrombocythemia Partiocipants |
3 |
2024-11-29 |
Anna Ravn Landtblom |
24/065 |
TAK-079-3002. A Phase 3, Randomized, Double-blind, Placebo-controlled Studyto Evaluate Efficacy and Safety of Mezagitamab SubcutaneousInjection in Participants with Chronic Primary ImmuneThrombocytopenia |
3 |
2024-06-24 |
Cecilia Karlström |
Lymfom
Nr | Namn | Fas |
Startdatum | Ansvarig prövare |
17/413 |
Immunologiska lab-studier på patienter med KLL och andra hematol. In vitro studier av immunologiska funktioner hos patienter med kroniska lymfoproliferativa tumörsjukdomar (Myelom, lymfom, KLL) och MGOS: Extra blodprovstagning |
Ej tillämpbar |
2018-01-01 |
Anders Österborg |
18/032 |
BioLymph. Prospektiv studie av biologi, etiologi och överlevnad vid lymfom (BioLymph) |
Ej tillämpbar |
2019-02-14 |
Karin Ekström Smedby |
18/073 |
PRO-Hodgkin. Clinical investigation of PBS proton treatment in Hodgkin lymphoma patients |
2 |
2019-11-06 |
Lotta Hansson |
19/085 |
POLAR BEAR-studien. R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial - NLG-LBC7 (POLAR BEAR) |
2 |
2021-02-01 |
Sara Harrysson |
20/007 |
DSA-LL-studien. Better and individualised therapy for patients with relapsing lymphoma and leukaemia |
Ej tillämpbar |
2021-09-01 |
Björn Wahlin |
20/058 |
ALLTogether-1. ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL) |
3 |
2020-09-01 |
Joel Joelsson |
20/070 |
PreVent-ACaLL. Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment who do not fulfil IWCLL treatment criteria for treatmnet. A randomized study with extensive immune phenotyping |
2 |
2022-08-15 |
Jeanette Lundin |
21/104 |
BGB3111-LTE1 Roll-overstudie. En öppen, multicenter, långsiktig förlängningsstudie av zanubrutinib (BGB-3111) hos patienter med Bcellsmaligniteter. |
4 |
2022-05-10 |
Björn Wahlin |
22/027 |
MERLIN. Phase II multicenter clinical trial:Mosunetuzumab for Early Relapse of Follicular Lymphoma inthe Nordic countries |
2 |
2023-12-14 |
Björn Wahlin |
22/073 |
BELLWAVE-011 (MK1026-011). A Phase 3, Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib as 1L+ Therapy in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) |
3 |
2024-10-10 |
Anders Österborg |
24/060 |
HYPERION. Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial |
2 |
2024-11-08 |
Björn Wahlin |
24/074 |
Golseek-1. A phase 3, multicenter, Randomized, Double-blind, Placebo-controlled study compairing the efficacy and safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP chemotherapy in participants with Previouslyu untreated High-risk large B-Cell lymphoma. |
3 |
2025-01-24 |
Kristina Sonnevi |
Myelom
Nr | Namn | Fas |
Startdatum | Ansvarig prövare |
22/009 |
MAGNETISMM-7-studien. A randomised, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation |
3 |
2022-09-08 |
Katarina Uttervall |
22/043 |
MajesTEC-7. A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy |
3 |
2022-12-22 |
Katarina Uttervall |
22/044 |
ODX-MM-001. A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma |
1-2 |
2023-03-28 |
Katarina Uttervall |
Koagulation
Nr | Namn | Fas |
Startdatum | Ansvarig prövare |
19/011 |
A-EKG-HemA. Kardiovaskulära risker och mikropartiklarnas roll i en åldrade population av patienter med hemofili A under olika behandlingsregim |
Ej tillämpbar |
2019-12-05 |
Roza Chaireti |
Övriga studier, flera diagnoser
Nr | Namn | Fas |
Startdatum | Ansvarig prövare |
19/010 |
Labmarkörer MPN-patienter . Labmarkörer som en del av riskbedömning för trombohemorrhagiska komplikationer hos patienter med myeloproliferativa sjukdomar |
Ej tillämpbar |
2021-12-06 |
Roza Chaireti |
Nr: Forskningsrådets nummer.
Namn: Studiens kortnamn följt av protokollets hela titel.
Fas: Kan vara Fas 1, 2, 3 eller Pilot, kombinationer av dessa, eller Ej tillämpligt.
Startdatum: Vanligen datum för startmöte eller
liknande.
Ansvarig prövare: Den läkare som är ansvarig
för studien inom Tema Cancer.
Ansvarig forskn.sköt: Den forskningssjuksköterska
som är ansvarig.
CKC, Tema Cancer, Karolinska universitetssjukhuset 03.07.2025